Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q4 2022
Institutional positions in Caribou Biosciences, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 133
- +20 vs. Q3 2022
- Shares held
- 43.6M
- +358.9K (+0.8%) vs. Q3 2022
- Total value
- $273.8M
- −$183.0M (−40.1%) vs. Q3 2022
- New holders
- 30
- 36 more added
- Sold out
- 10
- 38 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRBU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $84.8M |
| Q1 2026 | 137 | $71.3M |
| Q4 2025 | 124 | $58.8M |
| Q3 2025 | 117 | $87.0M |
| Q2 2025 | 129 | $51.2M |
| Q1 2025 | 131 | $45.8M |
| Q4 2024 | 133 | $93.1M |
| Q3 2024 | 129 | $103.1M |
| Q2 2024 | 140 | $87.6M |
| Q1 2024 | 151 | $343.0M |
| Q4 2023 | 144 | $395.8M |
| Q3 2023 | 126 | $338.5M |
| Q2 2023 | 121 | $185.5M |
| Q1 2023 | 126 | $238.3M |
| Q4 2022 | 133 | $273.8M |
| Q3 2022 | 113 | $456.8M |
| Q2 2022 | 120 | $203.0M |
| Q1 2022 | 104 | $313.2M |
| Q4 2021 | 93 | $464.7M |
| Q3 2021 | 88 | $704.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Caribou Biosciences, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 194,651 | $1.22M | 0.00% | +145,749+298.0% | Added |
| Rafferty Asset Management, LLC | 211,177 | $1.33M | 0.01% | +79,938+60.9% | Added |
| Mirae Asset Global Investments Co., Ltd. | 212,651 | $1.34M | 0.00% | −38,979−15.5% | Reduced |
| Norges Bank | 216,300 | $1.36M | 0.00% | −30,200−12.3% | Reduced |
| Granahan Investment Management Inc | 230,341 | $1.45M | 0.04% | −7,863−3.3% | Reduced |
| Millennium Management LLC | 240,043 | $1.51M | 0.00% | +3,928+1.7% | Added |
| International Biotechnology Trust PLC | 257,892 | $1.62M | 0.50% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 287,033 | $1.80M | 0.00% | −60,000−17.3% | Reduced |
| Point72 Asset Management, L.P. | 289,739 | $1.82M | 0.01% | +289,739 | New |
| Nuveen Asset Management, LLC | 306,886 | $1.93M | 0.00% | +83,479+37.4% | Added |
| Goldman Sachs Group Inc | 352,897 | $2.22M | 0.00% | −215,432−37.9% | Reduced |
| Charles Schwab Investment Management Inc | 404,902 | $2.54M | 0.00% | +6,191+1.6% | Added |
| 72 Investment Holdings, LLC | 474,067 | $2.98M | 1.37% | 00.0% | Unchanged |
| Northern Trust Corp | 534,487 | $3.36M | 0.00% | +11,329+2.2% | Added |
| Memorial Sloan Kettering Cancer Center | 544,196 | $3.42M | 11.27% | 00.0% | Unchanged |
| Tekla Capital Management LLC | 567,147 | $3.56M | 0.13% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 600,097 | $3.77M | 0.00% | −1,253−0.2% | Reduced |
| Maverick Capital LtdSuperinvestorMaverick Capital | 652,542 | $4.10M | 0.10% | 00.0% | Unchanged |
| Assenagon Asset Management S.A. | 854,738 | $5.37M | 0.02% | +55,247+6.9% | Added |
| FIL Ltd | 860,666 | $5.40M | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 1,030,987 | $6.47M | 0.00% | +45,617+4.6% | Added |
| Alkeon Capital Management LLC | 1,058,603 | $6.65M | 0.05% | −163,488−13.4% | Reduced |
| Morgan Stanley | 1,229,167 | $7.72M | 0.00% | +14,575+1.2% | Added |
| FMR LLC | 1,443,046 | $9.06M | 0.00% | −5470.0% | Reduced |
| Bank of America Corp | 1,843,902 | $11.6M | 0.00% | +1,668,395+950.6% | Added |
| Elmwood Wealth Management, Inc. | 2,364,240 | $14.8M | 7.45% | 00.0% | Unchanged |
| Pictet Asset Management SA | 2,553,878 | $16.0M | 0.02% | −737,020−22.4% | Reduced |
| Vanguard Group Inc | 2,580,217 | $16.2M | 0.00% | +26,789+1.0% | Added |
| Rokos Capital Management LLP | 2,748,139 | $17.3M | 1.74% | +840,630+44.1% | Added |
| Avidity Partners Management LP | 2,882,600 | $18.1M | 0.42% | −290,000−9.1% | Reduced |
| State Street Corp | 3,198,893 | $20.1M | 0.00% | +803,423+33.5% | Added |
| PFM Health Sciences, LP | 4,459,783 | $28.0M | 1.18% | −1,540,217−25.7% | Reduced |
| BlackRock Inc. | 4,722,083 | $29.7M | 0.00% | +243,893+5.4% | Added |
| Farallon Capital Management, L.L.C. | 0 | $0 | 0.00% | −896,369−100.0% | Sold out |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 0 | $0 | 0.00% | −271,430−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −83,101−100.0% | Sold out |
| Bellevue Group AG | 0 | $0 | 0.00% | −66,300−100.0% | Sold out |
| Kettle Hill Capital Management, LLC | 0 | $0 | 0.00% | −37,200−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −20,394−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −20,067−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −17,313−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −15,344−100.0% | Sold out |
| Castle Wealth Management LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |